Target
Bind DNABII proteins that help stabilize the biofilm’s extracellular DNA scaffold.
Biofilm
disrupters.
We’re developing human antibodies to break down bacterial biofilms and help antibiotics treat persistent infections.
A new category of bacterial biofilm disrupters.
Biofilms form a protective matrix around bacteria, making infections harder for antibiotics and the immune system to clear.
How TRL1068 works.
Calpurbatug (TRL1068) is an investigational native human monoclonal antibody designed to target DNABII proteins—the structural supports of a bacterial biofilm.
By removing these supports, TRL1068 can disrupt the biofilm matrix and release bacteria susceptible to antibiotics. We are currently pairing TRL1068 with antibiotics and surgical debridement to treat prosthetic joint infections.
The goal: control infection while preserving the patient’s implant.
Disrupt
Remove structural supports and destabilize the protective biofilm matrix.
Enable
Release bacteria from the biofilm so antibiotics can act on susceptible cells.
Rare human antibodies. CellSpot™.
Our proprietary CellSpot platform identifies rare, naturally occurring human monoclonal antibodies. It is the foundation of TRL1068 and a pipeline of programs targeting bacterial biofilms and viral infections.
Series D financing.
We’re raising a Series D to support the next clinical studies and manufacturing of TRL1068.
Talk to our teamSeries D financing$15–25M
Manufacturing scale-up, Phase 2 study readout and additional clinical trials.
Phase 2 fully enrolled
TRL1068 in prosthetic joint infection.
FDA development designations
Fast Track, Orphan Drug and QIDP for TRL1068.
Development and financing information reported in Trellis’s September 2026 investor deck.
Contact us.
Whether you’re an investor, a healthcare provider or a patient, we’d like to hear from you.